By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a model can be constructed how serotonin (5-HT) affects the vulnerability to induce tardive dyskinesia. From neuroanatomical studies, it can be concluded that 5-HT inhibits the release of dopamine (DA) within the dorsal striatum by affecting 5-HT2C receptors and also within the ventral striatum and prefrontal cortex by affecting 5-HT2A receptors. However, considering the low affinity of DA for its receptors, it is unlikely that the so released DA is able to displace atypical antipsychotics from DA D2 and D3 receptors. 5-HT2C receptors and, to a lesser extent, 5-HT2A receptors, have constitutive activity and therefore, atypical antipsychotics can...
The basal ganglia are a highly interconnected group of subcortical nuclei in the vertebrate brain th...
The neurotransmitter serotonin (5-HT) is involved in a number of mental disorders i.e. anxiety, depr...
L-DOPA, the most effective drug to treat motor symptoms of Parkinson's disease, causes abnormal invo...
By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a m...
By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a m...
Tardive dyskinesia (TD), a movement disorder produced by long-term treatment with a classical antips...
Background Tardive dyskinesia (TD) is a common side effect of antipsychotic treatment. This movement...
Objectives: An established theory for the pathogenesis of tardive dyskinesia is disturbed dopaminerg...
Tardive dyskinesia (TD), marked by abnormal involuntary movements and frequently expressed as perior...
Identifying biomarkers which can be used as a diagnostic tool is a major objective of pharmacogeneti...
Since the 1950s, when serotonin (5-HT) was discovered in the mammalian central nervous system (CNS),...
The neurotransmitters serotonin (5-HT) and dopamine (DA) play roles in eating disorders, mood disord...
In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-ind...
One explanation as to why atypical antipsychotic drugs (APDs e.g. clozapine) show reduced extrapyram...
International audienceThe serotonin (5-HT) syndrome occurs in humans after antidepressant overdose o...
The basal ganglia are a highly interconnected group of subcortical nuclei in the vertebrate brain th...
The neurotransmitter serotonin (5-HT) is involved in a number of mental disorders i.e. anxiety, depr...
L-DOPA, the most effective drug to treat motor symptoms of Parkinson's disease, causes abnormal invo...
By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a m...
By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a m...
Tardive dyskinesia (TD), a movement disorder produced by long-term treatment with a classical antips...
Background Tardive dyskinesia (TD) is a common side effect of antipsychotic treatment. This movement...
Objectives: An established theory for the pathogenesis of tardive dyskinesia is disturbed dopaminerg...
Tardive dyskinesia (TD), marked by abnormal involuntary movements and frequently expressed as perior...
Identifying biomarkers which can be used as a diagnostic tool is a major objective of pharmacogeneti...
Since the 1950s, when serotonin (5-HT) was discovered in the mammalian central nervous system (CNS),...
The neurotransmitters serotonin (5-HT) and dopamine (DA) play roles in eating disorders, mood disord...
In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-ind...
One explanation as to why atypical antipsychotic drugs (APDs e.g. clozapine) show reduced extrapyram...
International audienceThe serotonin (5-HT) syndrome occurs in humans after antidepressant overdose o...
The basal ganglia are a highly interconnected group of subcortical nuclei in the vertebrate brain th...
The neurotransmitter serotonin (5-HT) is involved in a number of mental disorders i.e. anxiety, depr...
L-DOPA, the most effective drug to treat motor symptoms of Parkinson's disease, causes abnormal invo...